Bortezomib是26S蛋白小体的高度选择性抑制剂，具有抗增殖、诱导凋亡以及抗新生血管生成等药理机制，已经在多发性骨髓瘤等肿瘤治疗中起到很好的疗效。Markovic
等进行了Bortezomib治疗转移性黑色素瘤的Ⅱ期临床研究，共有45个病人参加，研究未见客观有效，22%的患者病情稳定。
而Bcl-2的反义核苷酸抑制剂（Oblimersen sodium,G3139）也正在尝试应用于黑色素瘤的治疗，目前进一步临床研究尚在进行中。
参考文献
1.Daponte A, Ascierto PA, Gravina A,et al. Temozolomide and ci latin in
avdanced malignant melanoma. Anticancer Res. 2005 Mar-Apr;25(2B):1441-7.
2.Bafaloukos D, Tsoutsos D, Kalofonos H，et al. Temozolomide and ci latin versus
temozolomide in patients with advanced melanoma: a randomized phase II study of
the Hellenic Cooperative Oncology Group. A Oncol. 2005 Ju 16(6):950-7. Epub
2005 Apr 13.
3.De Gast GC, Batchelor D, Kersten MJ，et al. Temozolomide followed by combined
immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with
metastatic melanoma. Br J Cancer. 2003 Jan 27;88(2):175-80.
4.Reiriz AB, Richter MF, Fernandes S，et al. Phase II study of thalidomide in
patients with metastatic malignant melanoma. Melanoma Res. 2004
Dec;14(6):527-31.
5.Hwu WJ, Lis E, Menell JH, et al. Temozolomide plus thalidomide in patients
with brain metastases from melanoma. Cancer. 2005 Jun 15;103(12):2590-7.
6.Conill C, Fernandez-Ibiza J, Malvehy J,et al. Temozolomide in patients with
melanoma brain metastases treated with whole brain irradiation. Med Clin (Barc).
2004 Mar 27;122(11):413-5.
7.Fruehauf JP, Kong KM, Jakowatz JG.. Docetaxel and vinorelbine plus GM-CSF in
malignant melanoma. Oncology (Williston Park). 2005 Apr;19(4 Su l 2):19-22.
8.Ugurel S, Hilde rand R, Zimpfer A，et al. Lack of clinical efficacy of
imatinib in metastatic melanoma. Br J Cancer. 2005 Apr 25;92(8):1398-405.
9.Markovic , Geyer SM, Dawki F, et al. A phase Ⅱ study of bortezomib in the
treatment of metastatic malignant melanoma. Cancer.2005 June 15;103(12):2584-9.